The Andelyn Difference – Experience, Reliability, Scalability, and Efficiency

Mission ; Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients.

Vision ; Pioneering Solutions that turn Hope into Reality

Our Values are founded in our origin story.

The name “Andelyn” is a hybrid of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children’s Hospital. Andrew received the first U.S. investigational gene therapy for Duchenne muscular dystrophy in 2006. Evelyn received experimental gene therapy for spinal muscular atrophy in 2015. “Andelyn” combines their names, representing all the families who have courageously participated in the research that make today’s gene therapies possible.

Advancing Towards Clinical Testing Services